These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21517254)

  • 21. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.
    Moelans CB; de Weger RA; van Blokland MT; Ezendam C; Elshof S; Tilanus MG; van Diest PJ
    Cell Oncol; 2009; 31(1):1-10. PubMed ID: 19096145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy.
    Gatta LB; Incardona P; Cadei M; Grigolato P; Simoncelli S; Balzarini P
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):413-20. PubMed ID: 22417857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).
    Ghaffari SR; Sabokbar T; Dastan J; Rafati M; Moossavi S
    Asian Pac J Cancer Prev; 2011; 12(4):1031-4. PubMed ID: 21790246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
    Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
    J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular protocol for HER2/neu analysis in breast carcinoma].
    Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
    Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
    Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
    Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization.
    Sidoni A; Ferri I; Cavaliere A; Bellezza G; Scheibel M; Bucciarelli E
    Anticancer Res; 2006; 26(3B):2333-7. PubMed ID: 16821612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India.
    Panjwani P; Epari S; Karpate A; Shirsat H; Rajsekharan P; Basak R; Shet T; Chinoy R; Chacko R; Gursale S; Baraskar N; Gupta S; Hawaldar R; Desai S
    Indian J Med Res; 2010 Sep; 132():287-94. PubMed ID: 20847375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
    Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
    Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
    Al-Khattabi H; Kelany A; Buhmeida A; Al-Maghrabi J; Lari S; Chaudhary A; Gari M; Abuzenadah A; Al-Qahtani M
    Anticancer Res; 2010 Oct; 30(10):4081-8. PubMed ID: 21036723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.